Dexycu (dexamethasone intraocular injection) News

|||||||||| Dexycu (dexamethasone intraocular injection) / EyePoint Pharma
Clinical, P3 data, Journal: Safety of IBI-10090 for inflammation associated with cataract surgery: Phase 3 multicenter study. (Pubmed Central) - Nov 4, 2019
The safety and efficacy of IBI-10090 and prednisolone 1.0% were similar, with IBI-10090 preferred over drops.

|||||||||| Dextenza (dexamethasone punctal plug) / Ocular Therapeutix, Dexycu (dexamethasone intraocular injection) / EyePoint Pharma
Novel Drug Delivery Methods: Dextenza and Dexycu (ESPLANADE BALLROOM Moscone Center) - Oct 8, 2019 - Abstract #AAO2019AAO_3204;

|||||||||| dexamethasone / generics
Clinical, P3 data, Journal: Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Cataract Surgery: A Randomized, Placebo-Controlled, Phase III Trial. (Pubmed Central) - Sep 8, 2019
The safety and efficacy of IBI-10090 and prednisolone 1.0% were similar, with IBI-10090 preferred over drops. The IBI-10090 dexamethasone drug-delivery suspension placed in the anterior chamber after cataract surgery at concentrations of 342 and 517 μg was safe and effective in treating inflammation occurring after cataract surgery and may be an alternative to corticosteroid drop installation in this patient population.

||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
Trial completion, Surgery:  Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery (clinicaltrials.gov) -  Aug 17, 2017
P3, N=180, Completed,  Sponsor: ICON Bioscience Inc
The IBI-10090 dexamethasone drug-delivery suspension placed in the anterior chamber after cataract surgery at concentrations of 342 and 517 μg was safe and effective in treating inflammation occurring after cataract surgery and may be an alternative to corticosteroid drop installation in this patient population. Recruiting --> Completed

||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
Enrollment open, Trial primary completion date, Surgery:  Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery (clinicaltrials.gov) -  Jan 15, 2016
P3, N=180, Recruiting,  Sponsor: ICON Bioscience Inc
Recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Dec 2016

||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
New P3 trial, Surgery:  Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery (clinicaltrials.gov) -  Sep 14, 2015
P3, N=180, Not yet recruiting,  Sponsor: ICON Bioscience Inc

||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
Trial completion, Surgery:  The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery (clinicaltrials.gov) -  Mar 25, 2015
P3, N=394, Completed,  Sponsor: ICON Bioscience Inc
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed

||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
Enrollment closed, Surgery:  The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery (clinicaltrials.gov) -  Sep 5, 2014
P3, N=352, Active, not recruiting,  Sponsor: ICON Bioscience Inc
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
Enrollment open, Surgery:  The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery (clinicaltrials.gov) -  Jan 21, 2014
P3, N=352, Recruiting,  Sponsor: ICON Bioscience Inc
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting

||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
New P3 trial, Surgery:  The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery (clinicaltrials.gov) -  Dec 8, 2013
P3, N=352, Recruiting,  Sponsor: ICON Bioscience Inc

||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
Trial termination, Surgery:  Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients (clinicaltrials.gov) -  Sep 15, 2013
P2, N=42, Terminated,  Sponsor: ICON Bioscience Inc
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Study C11-01 started

||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
Enrollment change, Surgery:  Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients (clinicaltrials.gov) -  Sep 15, 2013
P2, N=42, Terminated,  Sponsor: ICON Bioscience Inc
Active, not recruiting --> Terminated; Study C11-01 started N=228 --> 42

||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
Enrollment change, Surgery:  Efficacy and Safety of IBI-10090 in Ocular Surgery Patients (clinicaltrials.gov) -  Jul 14, 2013
P2, N=172, Completed,  Sponsor: ICON Bioscience Inc
N=228 --> 42 N=228 --> 172

||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
Trial completion, Surgery:  Efficacy and Safety of IBI-10090 in Ocular Surgery Patients (clinicaltrials.gov) -  Jul 14, 2013
P2, N=172, Completed,  Sponsor: ICON Bioscience Inc
N=228 --> 172 Recruiting --> Completed

||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
New P2 trial, Surgery:  Efficacy and Safety of IBI-10090 in Ocular Surgery Patients (clinicaltrials.gov) -  May 24, 2012
P2, N=172, Completed,  Sponsor: ICON Bioscience Inc

||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
Enrollment change, Surgery:  Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery (clinicaltrials.gov) -  Mar 21, 2012
P2, N=6, Terminated,  Sponsor: ICON Bioscience Inc
Recruiting --> Completed N=228 --> 6



	Diseases Companies Products Productz Mechanisms of Action Sites